Cytokinetics Inc
CYTK
NASDAQ
Biotechnology
$74.13
USD
+0.68 (+0.93%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $10.36B
Volume 1.8M
Revenue
$67.67M
TTM
-21.1%
YoY
Gross Margin
92%
TTM
-6.1%
YoY
Net Income
$-894.00M
TTM
-47.4%
YoY
Operating Cash Flow
$-555.45M
TTM
-30.1%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 66.8 | 1.9 | 17.8 | 19.4 | 28.6 |
YoY Growth | +26714.9% | +318.1% | +4.9% | +1125.8% | -57.1% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 2.6 | 2.7 |
Gross Profit | 66.8 | 1.9 | 17.8 | 16.8 | 25.9 |
Selling, General & Administrative | 65.7 | 69.5 | 91.7 | 104.9 | 104.4 |
Other Operating Expenses | 2.4 | 0.0 | 0.0 | 0.0 | 2.9 |
Total Operating Expenses | 178.3 | 168.7 | 196.1 | 200.4 | 205.1 |
Operating Income | -111.5 | -166.8 | -178.4 | -183.6 | -179.2 |
EBITDA | -109.2 | -164.1 | -175.5 | -180.2 | -175.5 |
Other Income / Expense | -24.8 | -123.3 | 125.6 | -18.9 | -18.9 |
Total Other Income / Expense | -22.9 | -139.4 | 116.6 | -22.4 | -19.6 |
Income Before Income Taxes | -134.4 | -306.2 | -61.8 | -206.0 | -198.8 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -134.4 | -306.2 | -183.0 | -206.0 | -198.8 |
Consolidated Net Income / Loss | -134.4 | -306.2 | -61.8 | -206.0 | -198.8 |
Net Income Attributable to Common Shareholders | -134.4 | -306.2 | -183.0 | -206.0 | -198.8 |
Basic EPS | -$1.12 | -$2.55 | -$1.49 | -$1.67 | -$1.50 |
Diluted EPS | -$1.12 | -$2.55 | -$1.49 | -$1.67 | -$1.50 |
Basic Shares Outstanding | 119.5M | 120.0M | 122.5M | 123.3M | 132.1M |
Diluted Shares Outstanding | 119.5M | 120.0M | 122.5M | 123.3M | 132.1M |